Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
17 05 2023
Historique:
medline: 19 5 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

The objective of this study was to describe the frequency of resistance determinants in meropenem-nonsusceptible (MEM-NS)

Identifiants

pubmed: 37074173
doi: 10.1128/aac.01406-22
pmc: PMC10190273
doi:

Substances chimiques

Meropenem FV9J3JU8B1
Anti-Bacterial Agents 0
Bacterial Proteins 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0140622

Déclaration de conflit d'intérêts

The authors declare a conflict of interest. E.U. and G.S. are employees of Pfizer and hold stock/stock options. D.S. and M.E. are employees of IHMA, which received funding from Pfizer to run the ATLAS Global Surveillance Program. D.P. and A.M. received funding for collection of clinical bacterial isolates and sending them to IHMA.

Références

J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
Curr Infect Dis Rep. 2020 Feb 7;22(3):6
pubmed: 32034524
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
BMC Microbiol. 2017 Apr 27;17(1):101
pubmed: 28449650
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33753332
Front Microbiol. 2019 Jan 30;10:80
pubmed: 30761114
J Glob Antimicrob Resist. 2013 Mar;1(1):7-16
pubmed: 27873609
Ann Intensive Care. 2016 Dec;6(1):96
pubmed: 27714706
Biochem J. 2007 Jan 1;401(1):197-203
pubmed: 16961465
Infect Drug Resist. 2021 Jan 18;14:125-142
pubmed: 33500635
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32690645
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070467
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176
Int J Antimicrob Agents. 2013 Apr;41(4):325-9
pubmed: 23305656
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33
pubmed: 30895212
J Antimicrob Chemother. 2020 May 1;75(5):1165-1173
pubmed: 32040168
Antimicrob Agents Chemother. 2015;59(6):3606-10
pubmed: 25801558
Expert Rev Anti Infect Ther. 2021 Feb;19(2):197-213
pubmed: 32813566
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0200020
pubmed: 33972241
Clin Microbiol Rev. 2019 Jan 30;32(2):
pubmed: 30700432
Clin Microbiol Rev. 2019 Nov 13;33(1):
pubmed: 31722889

Auteurs

Mark Estabrook (M)

IHMA, Schaumburg, Illinois, USA.

Astrid Muyldermans (A)

Department of Microbiology and Infection Control, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Daniel Sahm (D)

IHMA, Schaumburg, Illinois, USA.

Denis Pierard (D)

Department of Microbiology and Infection Control, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Gregory Stone (G)

Pfizer Inc., Gorton, Connecticut, USA.

Eric Utt (E)

Pfizer Inc., Gorton, Connecticut, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH